EP11313 / Epigenetix, adMare BioInnovations - LARVOL DELTA

BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT. (PubMed, Front Immunol) - "However, BETi JQ1 interfered with Treg expansion and altered subset distribution and phenotype. Finally, using low numbers of highly purified expanded Tregs, improved clinical GVHD scores were observed in EP11313 treated recipients. In total, we conclude that use of this novel combinatorial strategy can suppress pre-clinical GVHD and posit, in vivo EP11313 treatment might be useful combined with Treg expansion therapy for treatment of diseases involving inflammatory responses."

Journal

Identification of a BET Bromodomain Inhibitor That Enables Treg Function: A Combinatorial Strategy to Inhibit Gvhd (TCT-ASBMT-CIBMTR 2019) - "...We found that the BETi EP11313 did not decrease frequency/numbers or phenotype of expanded Tregs (Figure 1) as well as effector molecules (IL-10 and TGF-). However, BETi JQ1 interfered with Treg proliferation and altered their phenotype...In total, we conclude that use of this novel combinatorial strategy can suppress pre-clinical GVHD. We propose that because BETi have demonstrated the ability to kill tumor cells, these compounds may provide additional anti-tumor activity together with GVL following allogeneic HSCT."